Satellos Bioscience (MSLE) Receivables - Other (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Receivables - Other came in at -$356000.0 in Q1 2026, down 463.27% year-on-year from $98000.0 in Q1 2025, and down 463.27% on a QoQ basis from $98000.0 in Q1 2025.
Satellos Bioscience (MSLE) Receivables - Other (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Receivables - Other data on file, last reported at -$356000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Satellos Bioscience | 182.60 Mn | 182.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -356,000.00 |
| Mar 31, 2026 | -356,000.00 |
| Mar 31, 2025 | 98,000.00 |
| Mar 31, 2025 | 98,000.00 |